Novel antibody helps patients with advanced gastric cancer live longer

Bookmark and Share
Published: 5 Jun 2016
Views: 1974
Prof Salah-Eddin Al-Batran - University Cancer Center, Frankfurt, Germany

Prof Al-Batran presents at ASCO 2016, findings from a European phase II study which showed that the novel, first-in- class antibody IMAB362 can significantly extend median survival when added to standard chemotherapy (13.2 months vs. 8.4 months) for patients with advanced gastric cancer.

Watch the video interview and read the news story for more.